
**Cardiovascular implants and artificial
organs — Cardiopulmonary bypass
systems — Arterial blood line filters**

*Implants cardiovasculaires et organes artificiels — Systèmes de
pontage cardio-pulmonaire — Filtres en ligne pour sang artériel*

STANDARDSISO.COM : Click to view the full PDF of ISO 15675:2009



PDF disclaimer

This PDF file may contain embedded typefaces. In accordance with Adobe's licensing policy, this file may be printed or viewed but shall not be edited unless the typefaces which are embedded are licensed to and installed on the computer performing the editing. In downloading this file, parties accept therein the responsibility of not infringing Adobe's licensing policy. The ISO Central Secretariat accepts no liability in this area.

Adobe is a trademark of Adobe Systems Incorporated.

Details of the software products used to create this PDF file can be found in the General Info relative to the file; the PDF-creation parameters were optimized for printing. Every care has been taken to ensure that the file is suitable for use by ISO member bodies. In the unlikely event that a problem relating to it is found, please inform the Central Secretariat at the address given below.

STANDARDSISO.COM : Click to view the full PDF of ISO 15675:2009



COPYRIGHT PROTECTED DOCUMENT

© ISO 2009

All rights reserved. Unless otherwise specified, no part of this publication may be reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying and microfilm, without permission in writing from either ISO at the address below or ISO's member body in the country of the requester.

ISO copyright office
Case postale 56 • CH-1211 Geneva 20
Tel. + 41 22 749 01 11
Fax + 41 22 749 09 47
E-mail copyright@iso.org
Web www.iso.org

Published in Switzerland

Contents

Page

Foreword.....	iv
1 Scope	1
2 Normative references	1
3 Terms and definitions.....	1
4 Requirements	2
4.1 Biological characteristics	2
4.2 Physical characteristics	2
4.3 Performance characteristics	3
5 Tests and measurements to determine compliance with this International Standard	3
5.1 General.....	3
5.2 Biological characteristics	4
5.3 Physical characteristics	4
5.4 Performance characteristics	4
6 Information supplied by the manufacturer	6
6.1 Information to be given on the arterial blood line filter	6
6.2 Information to be given on the packaging	6
6.3 Information to be given in the accompanying documents.....	7
6.4 Information to be given in the accompanying documents in a prominent form.....	8
7 Packaging	8
Bibliography	9

Foreword

ISO (the International Organization for Standardization) is a worldwide federation of national standards bodies (ISO member bodies). The work of preparing International Standards is normally carried out through ISO technical committees. Each member body interested in a subject for which a technical committee has been established has the right to be represented on that committee. International organizations, governmental and non-governmental, in liaison with ISO, also take part in the work. ISO collaborates closely with the International Electrotechnical Commission (IEC) on all matters of electrotechnical standardization.

International Standards are drafted in accordance with the rules given in the ISO/IEC Directives, Part 2.

The main task of technical committees is to prepare International Standards. Draft International Standards adopted by the technical committees are circulated to the member bodies for voting. Publication as an International Standard requires approval by at least 75 % of the member bodies casting a vote.

Attention is drawn to the possibility that some of the elements of this document may be the subject of patent rights. ISO shall not be held responsible for identifying any or all such patent rights.

ISO 15675 was prepared by Technical Committee ISO/TC 150, *Implants for surgery*, Subcommittee SC 2, *Cardiovascular implants and extracorporeal systems*.

This second edition cancels and replaces the first edition (ISO 15675:2001), which has been technically revised.

Cardiovascular implants and artificial organs — Cardiopulmonary bypass systems — Arterial blood line filters

1 Scope

This International Standard specifies requirements for sterile, single-use, arterial blood line filters intended to filter and remove emboli, debris, blood clots and other potentially hazardous solid and gaseous material from the blood of humans during cardiopulmonary bypass surgery.

2 Normative references

The following referenced documents are indispensable for the application of this document. For dated references, only the edition cited applies. For undated references, the latest edition of the referenced document (including any amendments) applies.

ISO 594-2, *Conical fittings with 6 % (Luer) taper for syringes, needles and certain other medical equipment — Part 2: Lock fittings*

ISO 10993-1, *Biological evaluation of medical devices — Part 1: Evaluation and testing*

ISO 10993-7, *Biological evaluation of medical devices — Part 7: Ethylene oxide sterilization residuals*

ISO 10993-11, *Biological evaluation of medical devices — Part 11: Tests for systemic toxicity*

ISO 11135:1994, *Medical devices — Validation and routine control of ethylene oxide sterilization*

ISO 11137-1, *Sterilization of health care products — Radiation — Part 1: Requirements for development, validation and routine control of a sterilization process for medical devices*

ISO 11607-1, *Packaging for terminally sterilized medical devices — Part 1: Requirements for materials, sterile barrier systems and packaging systems*

ISO 11607-2, *Packaging for terminally sterilized medical devices — Part 2: Validation requirements for forming, sealing and assembly processes*

ISO 14937, *Sterilization of health care products — General requirements for characterization of a sterilizing agent and the development, validation and routine control of a sterilization process*

ISO 17665-1, *Sterilization of health care products — Moist heat — Part 1: Requirements for the development, validation and routine control of a sterilization process for medical devices*

3 Terms and definitions

For the purposes of this document, the following terms and definitions apply:

3.1

arterial blood line filter

accessory device used as part of the cardiopulmonary bypass system in the arterial blood return line for filtering particles such as blood clots, debris and gas emboli from the blood

3.2

blood pathway

paths of the arterial blood line filter containing blood during its intended clinical use

3.3

blood cell damage

loss or destruction of cellular components of the blood components

3.4

platelet reduction

percentage reduction of platelets contained in a circuit incorporating an arterial blood line filter, less the percentage reduction in an identical control circuit without an arterial blood line filter, as a function of time

3.5

plasma-free haemoglobin level

difference between the concentration of plasma-free haemoglobin in a circuit incorporating an arterial blood line filter and the concentration in an identical control circuit without an arterial blood line filter, as a function of time

3.6

white blood cell reduction

percentage reduction of white blood cells contained in a circuit incorporating an arterial blood line filter, less the percentage reduction in an identical control circuit without an arterial blood line filter, as a function of time

3.7

filtration efficiency

ability of the filter to remove particles from the simulated blood suspension test fluid, expressed as a percentage

3.8

blood analogue

test solution which simulates blood viscosity

3.9

bubble eliminator

device that can remove bubbles

4 Requirements

4.1 Biological characteristics

4.1.1 Sterility and non-pyrogenicity

The blood pathway shall be sterile and non-pyrogenic. Compliance shall be verified in accordance with 5.2.1.

4.1.2 Biocompatibility

The parts of the blood pathway shall be biocompatible with respect to their intended use. Compliance shall be verified in accordance with 5.2.2.

4.2 Physical characteristics

4.2.1 Blood pathway integrity

When tested in accordance with 5.3.1, the blood pathway shall not leak.

4.2.2 Blood volume

The volume of the blood pathway shall be within the tolerances specified by the manufacturer (see 6.3).

4.2.3 Connectors

Connectors for connection to the blood pathway shall, when tested in accordance with 5.3.3, allow a secure connection. Connection for accessory ports shall meet the requirements of ISO 594-2.

NOTE Connectors of a type that allows connection of tubes with an inside diameter of 4,8 mm, 6,3 mm, 9,5 mm or 12,7 mm, or a type that complies with ISO 7199, have been found satisfactory.

4.3 Performance characteristics

4.3.1 Blood cell damage

When determined in accordance with 5.4.1, the percentage change (positive or negative) of plasma-free haemoglobin, platelets, and white blood cells, shall be within the range of values specified by the manufacturer.

4.3.2 Filtration efficiency

When tested in accordance with 5.4.2, the filtration efficiency of any individual filter shall be at least 80 % when tested with particles that are 20 % larger than the nominal pore size of the filter.

4.3.3 Flow rate capacity

When tested in accordance with 5.4.3, test results will demonstrate the flow rate and pressure limitation(s) to ensure safe and effective performance, as specified by the manufacturer.

4.3.4 Shelf life

When tested in accordance with 5.4.4, test results shall demonstrate the rated shelf life, as specified by the manufacturer.

4.3.5 Air-handling capability

When tested in accordance with 5.4.5, test results shall demonstrate the air-handling capability, as specified by the manufacturer.

5 Tests and measurements to determine compliance with this International Standard

5.1 General

5.1.1 Tests and measurements shall be performed with the device in its terminally sterilized form and prepared according to the manufacturer's instructions for intended clinical use.

5.1.2 Operating variables shall be those specified by the manufacturer for intended clinical use, unless otherwise specified.

5.1.3 Unless otherwise stated, the temperature of test liquids shall be $37\text{ °C} \pm 1\text{ °C}$.

5.1.4 If the relationship between variables is non-linear, sufficient determinations shall be made to permit valid interpolation between data points.

5.1.5 The test or measurement procedures shall be regarded as reference procedures. Other procedures can be accepted, provided that the alternative procedure has been shown to be of comparable precision.

5.2 Biological characteristics

5.2.1 Sterility and non-pyrogenicity

Compliance shall be verified by inspection of the manufacturer's documentation on sterilization and pyrogen testing, in accordance with ISO 17665-1, ISO 11135, ISO 11137-1, ISO 14937 or ISO 10993-11, as applicable.

5.2.2 Biocompatibility

Compliance shall be verified by test or by inspection of the manufacturer's documentation on biocompatibility for the finished device, in accordance with ISO 10993-1 and ISO 10993-7, as applicable.

5.3 Physical characteristics

5.3.1 Determination of blood pathway integrity (sterile final assembly)

Fill the blood pathway of the device with water and subject it to a positive pressure of $1.5 \times$ the manufacturer's rated pressure or, if none is given, to a pressure of 152 kPa (22 psi) gauge and maintain the pressure for 6 h or for the intended time of use specified by the manufacturer. Visually inspect the device for evidence of water leakage.

5.3.2 Test liquid

The test liquid shall be heparinized blood, or water.

The volume of the blood pathway shall be determined as specified by the manufacturer.

5.3.3 Connectors

The connection shall be made in accordance with the manufacturer's instructions for use.

The connection shall withstand a pull force of 15 N for 15 s without separating.

5.4 Performance characteristics

5.4.1 Blood cell damage

5.4.1.1 Test media

The test liquid for the blood pathway shall be heparinized blood.

5.4.1.2 Procedure

Two sets of appropriate, identical circuit components, including a pump, connecting tubing, a reservoir (as specified by the manufacturer and of suitable size relative to the device under test), and a heat exchanger, shall be assembled. The device under test shall be placed in one of the circuits. The blood pathway test-liquid volumes shall, at the initiation of the test, be within 1 % of each other. Perform the test *in vitro* using the conditions given in Table 1.

Table 1 — Conditions for *in vitro* testing of blood cell damage

Item	Level	Maximum variation
Blood flow rate	The maximum specified by the manufacturer for intended clinical use (see 6.3)	$\pm 5 \%$
Blood glucose	10 mmol/dl	± 5 mmol/dl
Haemoglobin	12 g/dl	± 1 g/dl

The sampling schedule shall be in accordance with Table 2.

Table 2 — Sampling schedule

Parameter	Time, after initiation of test (min)			
	Prior to test	30	180	360
Plasma-free haemoglobin	X	X	X	X
White blood cell	X	X	X	X
Platelets	X	X	X	X
Haemoglobin	X	X	X	X
Glucose	X			
Activated coagulation time	X	X	X	X
Temperature	X	X	X	X
Flow rates	X	X	X	X

5.4.2 Filtration efficiency

5.4.2.1 Test liquid

The test liquid shall be a glycerin solution or water. The test liquid shall contain 350 to 5 000 particles per ml that are 15 % to 25 % larger than the nominal pore size of the filter.

5.4.2.2 Procedure

Pass 500 ml of the test liquid at room temperature (20 °C to 22 °C) through the arterial blood line filter at a flow rate of no less than 100 ml/min and a pressure not exceeding 152 kPa (22 psi) gauge. Determine the pre- and post-filtration mean number of particles. The test shall be performed at the manufacturer's recommended flow rates. Calculate the filtration efficiency, using the readings from the size range of the test particles used for each test sample, by subtracting the post-filtration mean number of particles from the pre-filtration mean, dividing the quotient by the pre-filtration mean number of particles, and multiplying by 100 to obtain a percentage.

5.4.3 Filter flow rate

5.4.3.1 Test liquid

The test liquid shall be a blood analogue.

5.4.3.2 Procedure

Place the device under test in an appropriate test circuit. Set the flow rate at the maximum rated flow and monitor the inlet and outlet pressures across the filter for 6 h. Measure the flow rate using a calibrated flowmeter. Note any pressure changes during the test.

This test shall not take into account the effects of formed elements or proteinaceous aggregates.

5.4.4 Shelf life or expiry date

Using a documented method, artificially age finished, packaged devices in order to determine nominal shelf life. Repeat the aging process for five finished filters so as to have statistically relevant mean shelf life.

5.4.5 Air-handling capability

5.4.5.1 Test liquid

The test liquid shall be heparinized blood with a haemoglobin content of (12 ± 1) g/dl.

5.4.5.2 Procedure

Attach a 1 m vent tubing (3,2 mm I.D.) to the filter vent port and open it to the atmosphere at the other end. The back pressure at the maximum test flow shall be 26,6 kPa (3,9psi) ± 5 %. Use a bubble eliminator to measure any air downstream of the filter accumulated over a period of 5 min from bolus injection.

At flow rates of 33 %, 67 %, and 100 % of the specified maximum rated flow rate, 30 ml (10 ml for pediatric filters) of room air shall be injected as a single bolus.

5.4.5.3 Results

The results shall be reported as the percentage efficiency of gross air removal.

6 Information supplied by the manufacturer

6.1 Information to be given on the arterial blood line filter

The following information shall be given on the arterial blood line filter:

- a) the manufacturer's identity;
- b) model designation;
- c) the direction of blood flow.

6.2 Information to be given on the packaging

6.2.1 Information to be given on the unit container

The following shall be visible through or given on the unit container:

- a) the manufacturer's name and address;
- b) description of contents;

- c) model designation;
- d) statement on sterility and method of sterilization and non-pyrogenicity;
- e) expiry date;
- f) batch, lot or serial number designation;
- g) the words, "Read instructions before use" or equivalent symbol;
- h) any special handling or storage conditions;
- i) statement on single-use.

6.2.2 Information to be given on the shipping container

The following information shall appear on the shipping container:

- a) the manufacturer's name and address;
- b) description of contents, including number of units;
- c) model designation;
- d) expiry date;
- e) any special handling, storage or unpacking instructions.

6.3 Information to be given in the accompanying documents

Each shelf box shall contain an "Instructions for Use" leaflet with the following information:

- a) the manufacturer's address and telephone or telefax numbers;
- b) model designation;
- c) required ancillary equipment;
- d) instructions on necessary, special or unique procedures, as applicable;
- e) directions for placing the filter in a support or operational fixture;
- f) placement, type and securing of tubing connections;
- g) location and purpose of additional entry or exit ports;
- h) priming procedure;
- i) direction of blood flow;
- j) general operating procedures for normal use;
- k) air-handling capability;
- l) maximum and minimum recommended blood flow rates;
- m) priming volume;